Trial reportEuropean journal of clinical pharmacology2018
Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients.
Trial report in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 6 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Brain-derived neurotrophic factor (BDNF) epigenomic modifications and brain-related phenotypes in humans: A systematic review.Neuroscience and biobehavioral reviews · 2023Pooled it
- Research trend of epigenetics and depression: adolescents' research needs to strengthen.Frontiers in neuroscience · 2023Pooled it
- A systematic review of childhood maltreatment and DNA methylation: candidate gene and epigenome-wide approaches.Translational psychiatry · 2021Pooled it
- BDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder.Behavioural neurology · 2021Pooled it
- The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Trial
- Neurotrophin System as a Complex Set of Potential Biomarkers in Psychiatric Disorders and Therapy-Overview of Recent Advances.International journal of molecular sciences · 2026Review
- Epigenetic profiles of response to transcranial magnetic stimulation in treatment resistant depression.BMC medical genomics · 2025Article
- Genome-wide association and DNA methylation analyses of SSRI treatment response in major depressive disorder.BMC psychiatry · 2025Article
- Pharmaco-Multiomics: A New Frontier in Precision Psychiatry.International journal of molecular sciences · 2025Review
- Epigenetic mechanisms of rapid-acting antidepressants.Translational psychiatry · 2024Review
- The Psychoneuroimmunological Model of Moral Distress and Health in Healthcare Workers: Toward Individual and System-Level Solutions.Comprehensive psychoneuroendocrinology · 2024Review
- The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.Genes · 2023Review
- Review
- Childhood adverse events andFrontiers in psychiatry · 2023Article
- BDNF exon IV promoter methylation and antidepressant action: a complex interplay.Clinical epigenetics · 2022Article
- BDNF as a Mediator of Antidepressant Response: Recent Advances and Lifestyle Interactions.International journal of molecular sciences · 2022Review
- Depressive disorder and antidepressants from an epigenetic point of view.World journal of psychiatry · 2022Review
- RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients.BMC psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe neurotrophin brain-derived neurotrophic factor (BDNF) has been found to be associated with both the pathophysiology of depression and antidepressants response. Gene expression differences were partly mediated by SNP, which might be identified as a predictor of antidepressant response. In the present study, we attempt to identify whether DNA methylation, another factor known to affect gene transcription, might also predict antidepressant response.
methodsA total of 85 depressed Chinese Han patients were followed-up 8 weeks after initiating escitalopram treatment. Treatment response was assessed by changes in the Hamilton Depression Rating Scale-17 (HAMD-17) score. The Life Events Scale (LES) and the Childhood Trauma Questionnaire (CTQ) were utilized as the assessment of previous life stress. The bisulfate sequencing was used to assess DNA methylation. Four single nucleotide polymorphisms (SNPs) in the BDNF gene were genotyped using PCR-RFLP or PCR sequencing.
resultsWe identified a DNA methylation predictor (P = 0.006-0.036) and a DNA methylation by LES interaction predictor (OR = 1.442 [1.057-1.968], P = 0.021) of general antidepressant treatment response. Lower mean BDNF DNA methylation was associated with impaired antidepressant response. Furthermore, the present data indicated that age, life stress, and SNPs genotype might be likely related to DNA methylation status. Average DNA methylation of BDNF at baseline was significantly lower than that at endpoint after 8 weeks of escitalopram treatment, which was based only on a subset of cases (n = 44).
conclusionsOur results suggest that BDNF DNA hypomethylation and its interaction with lower LES score might result in impaired antidepressant treatment response. The pharmacoepigenetic study could eventually help in finding epigenetic biomarkers of antidepressant response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.